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ABSTRACT 
Public Health Significance: Treatment as prevention (TasP) could be an effective way to 
address the HIV epidemic among Black transgender women (BTW) in the United States. For 
TasP to be effective in this population, more information regarding the manifestation of HIV 
care continuum outcomes among BTW is needed.  
Methods: Data came from Promoting Our Worth, Equality, and Resilience (POWER). In 2014 
and 2015, POWER recruited Black men who have sex with men (BMSM) and BTW who 
attended Black Pride events in Philadelphia, PA, Houston, TX, Washington, D.C., Detroit, MI, 
Memphis, TN, and Atlanta, GA. A total of 245 BTW provided complete data for our analysis. 
Results: We detected an HIV prevalence rate of 37.8%. Of the 92 HIV-positive BTW, 50% had 
prior knowledge of their HIV-positive status. 100% of those with prior knowledge of their HIV-
positive status reported that they were linked to HIV medical care. 93% of HIV-positive BTW 
linked to HIV medical care reported that they were retained in HIV medical care, and 95% of 
those retained in HIV medical care reported that they had been prescribed antiretrovirals 
(ARVs). 68% of the 41 HIV-positive BTW prescribed ARVs reported that they had an 
undetectable viral load. Health outcomes associated with HIV care in other populations were not 
associated with HIV diagnosis or viral suppression in our sample. 
Conclusion: Developing and implementing interventions that address testing uptake may assist 
in informing the HIV disparity among BTW in the United States. More research is needed to 
identify and understand the structural, community, and individual-level barriers and facilitators 
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Transgender women experience high rates of HIV infection. A 2008 meta-analysis 
reported an HIV prevalence of 28% in this population, with markedly higher prevalence (56%) 
among Black transgender women (BTW) [1]. Given the high prevalence of HIV infection in this 
population, treatment as prevention (TasP) could be an effective way to prevent additional HIV 
infection among BTW as it is widely supported as a means to lower HIV incidence [2-4]. 
However, before we can develop and implement TasP interventions among BTW, we need to 
characterize the HIV care continuum and identify correlates of HIV care in this population. 
While several characterizations of the HIV care continuum include transgender women alongside 
samples of men who have sex with men (MSM), few examine these outcomes among 
transgender women exclusively [5, 6]. To our knowledge, no characterizations of the HIV care 
continuum among BTW exist, a major gap if TasP is to be effectively implemented among 
BTW. Interventions require knowledge of which stage of HIV care continuum patients 
experience barriers in order to address them.  
In order to address barriers that keep patients from progressing along the HIV care 
continuum, we need to know what differentiates BTW who get stuck at one stage from those 
who progress. Little information is available regarding such barriers among BTW [7, 8]. BTW 
have limited access to education, housing, and health care opportunities [1]. Compared to the 
general population, BTW have achieved fewer years of education, experience higher rates of 
homelessness, and have been less likely to access medical care [1]. Additionally, BTW 
experience high rates of incarceration, engagement in sex work, experiences of physical assault, 
intimate partner violence, depression and substance use [1]. As these factors are associated with 
HIV care continuum outcomes in other populations [9-13], and because formative research 
among transgender women identified these outcomes as potential barriers to HIV testing and 
care [7], they warrant examination. In addition to these outcomes, social support should also be 
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explored. Formative research among transgender women identified the support of friends and 
family as potential facilitator to HIV care [7]. 
This exploratory study seeks to fill aforementioned gaps in the literature by: (1) 
determining the prevalence of HIV care continuum outcomes, and (2) exploring correlates of 







2.1 STUDY DESIGN AND POPULATION 
 
 
Data came from the Promoting, Our Worth, Equality, and Resilience (POWER) study. In 
2014 and 2015, POWER employed time-location sampling to recruit men who have sex with 
men and transgender women at Black Pride events in six cities: Atlanta, GA; Detroit, MI; 
Houston, TX; Memphis, TN; Philadelphia, PA; and Washington, DC. Individuals were eligible 
to participate if they: (1) were assigned male sex at birth; (2) reported having a male sexual 
partner in their lifetime; and (3) were 18 years or older. This study only includes those who: (1) 
identified as “Black” or “African American”; and (2) identified as female, transgender, or 
reported having transitioned from male to female gender. 
Participants completed an anonymous self-administered, computer-assisted, behavioral 
health questionnaire on electronic tablets designed to take approximately 20 minutes to 
complete. To prevent duplication of participants in our sample, we asked participants a series of 
questions to create a unique identifier code [14]. Anyone with duplicate questionnaire data had 
only their first response included in the current investigation.  
Upon completion of the behavioral health questionnaire, POWER offered every 
participant confidential HIV testing. Confidential HIV testing was performed onsite by local 
community based organizations (CBOs). CBOs utilized their own rapid HIV-testing protocol, 
and used either the Oraquick (OraSure Technologies, Inc., Bethlehem, PA) Clearview STAT-
PAK (Alere Inc., Waltham, MA), or INSTI (bioLythical Laboratories, Richmond, BC) test. 
Confirmatory testing of preliminary positive results using Western Blot was performed offsite at 
a later date. Participants electing confidential HIV testing received their test result and $20. If a 
participant declined confidential HIV testing, POWER staff offered anonymous HIV testing. 
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POWER staff used OraQuick for oral fluid to provide anonymous HIV testing. Those electing 
for anonymous testing did not receive their HIV test result but did receive $20. Participants 
declining either form of HIV testing were paid $10 for completion of the survey. HIV test results 
were anonymously linked to survey files via a unique subject ID. All study procedures were 









 HIV status was assessed with a combination of biological and self-report data. HIV-
positive status was determined if participants had a preliminary HIV-positive test result, or 
responded “HIV-positive” to the following question: “What was the result of your most recent 
HIV test?” Unlike HIV-positive status, HIV-negative status had to be confirmed via HIV test 
result. Serostatus was coded as missing for all participants who assayed biologically 
indeterminate, with the exception of those who self-identified as HIV-positive.  
Knowledge of HIV-Positive Status  
Self-report and biological data were used to assess previously undiagnosed HIV-positive 
status. Previously diagnosed HIV-positive status was determined if participants identified 
themselves as HIV-positive in the questionnaire. Previously undiagnosed HIV-positive was 
determined if participants received a HIV-positive test result and responded “HIV-negative,” 
“Indeterminate,” or “I don’t know,” when asked about the result of their most recent HIV test.  
Remaining HIV Care Continuum Outcomes: Linkage, Retention, ART prescription, and Viral 
Suppression 
Assessment of linkage to HIV medical care used the following yes/no item: “Have you 
ever been seen by a doctor, nurse, or other health care provider for a medical evaluation or care 
related to your HIV infection?” Retention in HIV medical care was measured with the following 
item: “Are you currently being seen by a doctor, nurse, or other health care provider for a 
medical evaluation or care related to your HIV infection?” Assessment of prescription of anti-
retroviral medications (ARVs) was assessed with the question: “Are you currently taking 
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antiretroviral medicines to treat your HIV infection?  To determine viral load one item was used: 
“What were the results of your most recent HIV lab tests? (Viral load)” with four responses (1) 
undetectable; (2) detectable, but under 10,000; (3) 10,000 - 100,000: and (4) Higher than 
100,000.” This variable was recoded as a dichotomous outcome: undetectable (response 1) or 
detectable (response 2, 3, or 4). 
Depression 
 The Center for Epidemiologic Studies Depression 10 (CES-D 10; Cronbach’s 
alpha=0.74) measured past-week depressive symptomatology [15].  The scale was dichotomized 
so that individuals with scores of 10 or greater were considered to have sufficient depressive 
symptomology consistent with major or clinical depression [15].  
Poly-Substance Use 
 Past-year poly-substance use was operationalized as the use of two or more of the 
following substances in the last 12-months: poppers, crack cocaine, cocaine, methamphetamines, 
heroin, non-prescribed prescription opiates (e.g., Vicodin, OxyContin), or party drugs other than 
methamphetamine (e.g., MDMA, ecstasy, GHB). 
Physical Assault  
Measurement of physical assault used the following yes/no item: “In the past year have 
you been physically assaulted (hit, kicked, beat up or in any other way physically harmed)?”  
Intimate Partner Violence 
Intimate partner violence was assessed with the following yes/no item: “In the past year, 
have you been in a relationship with a partner who has ever hit, kicked, slapped, beaten or in any 
other way physically assaulted you?” 
Social Support  
Family and friend support were measured with the following question: “To what degree to you 
feel you receive support from your family/friends? none, a little, somewhat, a lot.”  
Incarceration 
 Assessment of incarceration used was measured with the following yes/no item: “In the 






Homelessness was assessed with the following yes/no item: “In the past 12 months have 
you been homeless at any time?  By homeless, I mean you were living on the street, in a shelter, 
in a Single Room Occupancy hotel (SRO), or in a car.”  
Sex work  
Two questions measured engagement in sex work. “In the past 12 months, did you ever 
give or take money, drugs or other goods for sex with a female partner? (Check all that apply);” 
the question was repeated for male partners. Response options included: “No;” “Yes, I received 
money, drugs or other goods for sex;” and “Yes, I gave money, drugs or other goods for sex.” 
Participants were considered to have engaged in sex work if they received money, drugs, or 
goods for sex with either a female or male partner. 
Health Insurance Coverage and Access to Medical Care 
 The presence of health insurance coverage was measured with the following yes/no item: 
“Do you currently have health insurance or health care coverage?” Access to medical care was 
assessed with the yes/no item: “During the past 12 months, was there any time when you needed 
medical care but didn’t get it because you couldn’t afford it?” 
Demographics 
Age, education, and city of data collection were also assessed. Age was measured in 
years, and four levels were used to measure education: less than high school, high school 








Of the 290 BTW who completed the survey, 15.5% were missing data on at least one 
variable in our analysis. Bivariate analyses compared demographics of those with no missing 
data to those missing data on at least one variable; there was no significant difference between 
the two groups so we removed those with missing data using listwise deletion, creating an 
analytic sample of 245 participants.  
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Bivariate analysis compared diagnosed HIV-positive BTW to undiagnosed HIV-positive 
BTW as well as diagnosed HIV-positive BTW with an undetectable viral load to diagnosed HIV-
positive BTW with a detectable viral load. We used chi-square tests for categorical variables and 
t-tests for continuous variables. We conducted analyses in SAS version 9.4 , (SAS Institute, Inc., 
Cary, NC) and all significance was set at alpha = 0.05.
8 
3.0 RESULTS 
Table 3.1 shows sociodemographic characteristics of the 245 BTW in the sample. The mean 
age was 29.9 (range: 18-84); 26.9% of the sample had not completed high school, and 79.6% of 
the sample had some form of health insurance and/or coverage. In the past two years, 34.7% of 
BTW had been incarcerated, and in the past-year 42.0% of BTW had been homeless, 18.9% had 
engaged in sex work with male and/or female partners, and 46.3% had experienced physical 
assault. HIV prevalence in the sample was 37.6% (n=92).  
Figure 3.1 depicts the HIV care continuum among the HIV-positive BTW in our sample. 
Of the 92 HIV-positive BTW, 50% (n=46) had prior knowledge of their HIV-positive status. 
100% (n=46) of those with prior knowledge of their HIV-positive status were linked to HIV 
medical care. 93% (n=43) of HIV-positive BTW linked to HIV medical care were retained in 
HIV medical care, and 95% (n=41) of those retained in HIV medical care had been prescribed 
antiretrovirals (ARVs). 68% (n=28) of the 41 HIV-positive BTW prescribed ARVs had an 
undetectable viral load.  
Table 3.2 shows a comparison of diagnosed HIV-positive BTW to undiagnosed HIV-
positive BTW. Undiagnosed HIV-positive BTW reported completing marginally fewer years of 
education, (p=0.07) and had marginally higher levels of incarceration (p=0.06) and friend 
support (p=0.06). Undiagnosed HIV-positive BTW also reported significantly lower levels of 
depression. For example, 45.7% of undiagnosed HIV-positive BTW reported being depressed 
compared to 67.4% of diagnosed HIV-positive BTW. 
Table 3.2 also shows a comparison of diagnosed HIV-positive BTW with an undetectable 
viral load to diagnosed HIV-positive BTW with a detectable viral load.  BTW with an 
undetectable viral load reported marginally lower levels of incarceration (p=0.06) and poly-
substance use (p=0.06). BTW with a detectable viral load reported significantly higher levels of 
family support than BTW with an undetectable viral load; 56.3% of BTW with a detectable viral 
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load indicated they somewhat felt they received support from their family compared to 14.3% of 








  % (n)  
Demographics  
 Education 
 Less than high school 26.9 (66) 
High School diploma 32.2 (79) 
Some college 22.9 (56) 
College diploma or more 18.0 (44) 
City 
 Philadelphia, PA 11.4 (28) 
Houston, TX 24.9 (61) 
Washington, D.C. 17.6 (43) 
Detroit, MI 24.1 (59) 
Atlanta, GA 20.4 (50) 
Memphis, TN 1.6 (4) 
Age mean (standard deviation) 29.9 (10.2) 
Health care 
 Presence of health coverage  79.6 (195) 
Able to access care  56.3 (138) 
Hypothesized correlates of HIV 
care continuum outcomes 
 Incarceration 34.7 (85) 
Homelessness 42.0 (103) 
Sex work 18.9 (46) 
Poly-substance use 23.7 (58) 
Depression 50 (123) 
Physical Assault  46.3 (113) 
Intimate Partner Violence 49.4 (121) 
Family Support 
 None 64 (26.1) 
A little 73 (29.8) 
Somewhat 43 (17.6) 
A lot  65 (26.5) 
Friend Support 
 None 60 (24.5) 
A little 63 (25.7) 
Somewhat 43 (17.6) 
A lot  79 (32.2) 





























Diagnosed Linked to Care Retained in Care Prescribed ARVs Virally Suppressed
HIV Care Continuum among HIV positive BTW:
United States, 2014-2015
100% 93% 95% 68%
 11 
Table 3.2: Comparison of diagnosed HIV-positive black transgender women (BTW) to undiagnosed HIV-positive 




























    % (n)    % (n)    p   % (n)    % (n)   p 
Demographics 
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High School diploma 28.3 (13) 
 
39.1 (18) 




  Some college 28.3 (13) 
 
19.6 (9)   




  College diploma or more 26.1 (12) 
 
15.2 (7) 






































Hypothesized correlates of HIV 
care continuum outcomes 

























































































A little 23.9 (11) 
 
32.6 (15) 




  Somewhat 28.3 (13) 
 
10.9 (5) 




  A lot  28.3 (13) 
 
28.3 (13) 




  Friend Support 











A little 19.6 (9) 
 
19.6 (9) 




  Somewhat 30.4 (14) 
 
15.2 (7) 












4.1 DISCUSSION AND RECOMMENDATIONS 
 
 
The results of our study show HIV is endemic among BTW. Thirty-seven percent of 
BTW in our sample are living with HIV. However, our results also suggest that once diagnosis 
occurs for HIV-positive BTW, the majority of these BTW report being linked to care, retained in 
care, and prescribed ARVs. Though only 50% of HIV-positive BTW had prior knowledge of 
their HIV-positive status, 100% of diagnosed HIV-positive BTW reported linkage to HIV care, 
93.5% retention in HIV care, 89.1% prescribed ARVs, and 60.9% reported achieving an 
undetectable viral load. Though these estimates may reflect higher uptake of medical care than 
those seen in the larger population of HIV-positive people in the U.S. [16], they suggest 
interventions should target unknown HIV-positivity among BTW. 
BTW need to be a priority population for interventions that address HIV diagnosis in the 
United States. According to the Medical Monitoring Project, 18.1% of persons living with HIV 
in the United States are undiagnosed [16], which makes the 50% prevalence of undiagnosed 
HIV-positivity in our sample much higher than those reported for other high risk populations. 
Fatalism and avoidance could explain this disparity. BTW experience significant difficulties 
when attempting to access HIV testing and care services. Barriers are often related to instances 
of transphobia and discrimination and include a lack of transgender inclusive/affirming providers 
and organization [17, 18]. Formative research among BTW found that though BTW felt their 
HIV infection was inevitable, they were hesitant to obtain an HIV test fearing they might receive 
a stigmatized diagnosis that would require they access additional, possibly stigmatizing health 
care [7]. Considering this view within the framework of the Transtheoretical Model  [19] could 
possibly explain our HIV care continuum findings.  Perhaps the pre-contemplation
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contemplation, and planning stages for accessing HIV-testing and accessing HIV-medical care 
are the same for BTW. Once BTW take action to access testing and learn of their HIV-positive 
status, they are ready to take action to access HIV medical care. In order to advance TasP among 
HIV-positive BTW, future research should explore this hypothesis.  
We compared diagnosed HIV-positive BTW to undiagnosed HIV-positive BTW to 
identify correlates of an undiagnosed HIV-positive status in this population. Diagnosed HIV-
positive BTW had significantly higher levels of depression. However, because the frequency of 
major depressive disorders is higher among HIV-positive individuals compared to HIV-negative 
individuals, having been diagnosed HIV-positive most likely explains this difference [20]. 
Diagnosed HIV-positive BTW in our sample had marginally higher levels of education and 
friend support and a marginally lower frequency of incarceration than undiagnosed HIV-positive 
BTW. Though these findings were not statistically significant, given low and medium education 
level, recent incarceration, and lower levels of social support have been associated with delayed 
HIV-diagnosis in other populations [21-23], they most likely would be with a larger sample of 
HIV-positive BTW. In view of these findings, social network strategy could be an effective way 
to identify HIV-positive BTW. Social network strategy has successfully identified undiagnosed 
HIV-positivity among African-American women and Black MSM (BMSM) populations [24, 25], 
and BTW cite social support as an important facilitator to HIV testing and care [7]. 
While there were marginal differences in some factors we normally associated with HIV 
care continuum outcomes in other populations, there was no difference in rates of homelessness, 
engagement in sex work, poly-substance use, physical assault, and intimate partner violence [26]. 
How do we explain these null findings in a way that conveys their importance and advances the 
field of TasP research among BTW? One way is to consider the very high prevalence rates of 
these health outcomes in the overall sample. This could lead to a ceiling effect, and therefore 
eliminate differences between undiagnosed and diagnosed HIV-positive BTW. The prevalence 
of these health outcomes in our sample as a whole is concerning. While they were not found to 
be associated with HIV care continuum outcomes, considering how they manifest in other HIV-
positive populations [12, 27], these health outcomes are most likely problematic to the 
advancement of TasP among BTW.  
In order to address the HIV disparity and advance TasP in this population, we must 
utilize a holistic approach to HIV care. BTW face a multiplicity of challenges to health and well-
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being [1], and according to formative research, such challenges threaten the effectiveness of 
TasP in this population [7, 12, 27]. The frequency of homelessness, sex work, and experiences of 
physical assault in our sample most likely result from societal stigma, limited employment, 
education, and housing opportunities available to BTW [28]. Therefore, interventions addressing 
structural inequity are necessary to alleviate experiences of these outcomes. Federal laws that 
prohibit discrimination based on gender identity in the areas of employment, housing, public 
accommodation, social services and access to credit are necessary, as are interventions designed 








While there were notable strengths to our methods, our analysis is not without 
limitations. The most notable being the utilization of self-report data to characterize the HIV care 
continuum among BTW. Studies have shown a discrepancy between self-report and clinical 
evaluation of unknown HIV-positivity among men who have sex with men (MSM) [30, 31] as 
there may be social desirability bias related to self-report HIV status, linkage to and retention in 
care, ARV adherence, and viral suppression. Therefore, our data may overestimate the number of 
HIV-positive BTW at each point of the HIV care continuum. Additionally, our retention in HIV 
medical care measure may overestimate the number of BTW retained in care. Though there is no 
gold standard for measuring retention in HIV care [32], our measure of retention in care is not 
clearly defined. Asking participants if they are currently being seen for HIV medical care does 
not measure concrete aspects of retention in care (e.g. missed visits, appointment adherence, visit 
consistency or gaps in care) as the literature suggests [33].  
Our findings are not necessarily generalizable to all BTW. BTW who attend Black Pride 
events may be different than those who do not attend Black Pride events. Factors regarding travel 
such as money and the ability to take time off of work or school could influence attendance of 
Black Pride events. Additionally, our findings may not accurately capture the manifestation of 
health outcomes among BTW. Though BTW were eligible to participate in POWER, POWER’s 
primary study population was BMSM. Therefore, POWER utilized a questionnaire designed to 
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capture the lived experiences of BMSM rather than those of BTW. It is possible measures used 
in this study need to be reframed for BTW. For example, the prevalence of homelessness and 
physical assault in our sample suggests a need to measure these outcomes with shorter time 
intervals; in addition to past-year measures, past-three month measures could be employed. It is 
also possible that measures need to be added in order to better explore correlates HIV care 
continuum outcomes in this population. BTW have different health needs than their non-
transgender peers. Many BTW may choose to reconcile their gender identity with anatomy and 
physiology through transgender affirming medical care. Utilization of such care could prove to 
be a barrier or facilitator to HIV testing and treatment [7, 34-36], and therefore could have 
implications for the effectiveness of TasP in this population. Because questions pertaining to 
transgender affirming medical care were not asked until 2015, the sample of HIV-positive BTW 
who answered these questions (n=35) was small. Therefore, we could not adequately explore 
their associations with HIV care continuum outcomes in this subsample of HIV-positive BTW. 
Finally, small sample size limited our analysis. Though characterizing the HIV care 
continuum among HIV-positive BTW is a good way to identify targets for interventions, simple 
characterization does not explicate means by which such disparities can be attenuated. Without 
such knowledge, intervention development cannot move forward. In order to explore 
associations with progression along the HIV care continuum, larger samples of HIV-positive 








The disparity of undiagnosed HIV-positivity within this population has negative health 
effects for BTW and members of their sexual networks. In order for TasP to be effective, BTW 
need to be a priority population for interventions that address HIV diagnosis in the U.S. 
However, we cannot begin to develop and implement such interventions until we understand 
how the overall health of BTW affects HIV care continuum outcomes. BTW face many 
challenges to health and well-being, and frequencies of negative health outcomes in our sample 
supports this claim. Because of these amplified disparities, BTW need to be more fully 
represented in research. Despite being disproportionately burdened by HIV, BTW continue to be 
underrepresented in existing HIV/AIDS research, and when BTW are represented, they are most 
often grouped with BMSM [37]. Fuller representation could produce larger samples of HIV-
positive BTW and better explore how amplified health disparities among BTW affect HIV care 
continuum outcomes. Though BTW make up only a small portion of HIV-positive individuals in 
the United States. Given the high HIV prevalence in this population, advancing TasP among 
BTW should be a priority. Viral suppression, the ultimate goal of TasP, is important to the health 
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